Evox Therapeutics upgrades its facilities at The Oxford Science Park

| By | Biotechnologies, Innovative Medicines, R&D

Evox Therapeutics, a UK leading exosome therapeutics company, announced it has expanded into a new laboratory and office space at The Oxford Science Park, to enhance its research and development (R&D) capabilities.

Following its inception in 2016, Evox has continued to advance its groundbreaking exosome research. This expansion reflects the growing interest and demand in the exosome-based biotherapeutics field and will provide access to the R&D facilities and equipment needed to accelerate the Company’s growth.

As part of the move, Evox is expecting to create over a dozen new job opportunities in the area over the near-term. The new space significantly increases the Company’s overall footprint and includes state-of-the-art laboratories, providing cleanroom capabilities and a tissue culture / process development laboratory suitable to prepare material for pre-clinical studies.

Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of biotherapeutics. Evox has created substantial proprietary technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of protein, antibody and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies, and Evox is leading the development within this emerging therapeutic space.

SOURCE: evox therapeutics
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.